Using technology created by a researcher at UTHealth Houston, a new study shows that the presence of a misfolded alpha-synuclein protein can be used to identify persons with Parkinson’s disease. The discovery of this biomarker may lead to the creation of more accurate diagnostic equipment and innovative disease-modifying therapies. The Michael J. Fox Foundation for Parkinson’s Research contributed funding to the study, which was overseen by Claudio Soto, PhD, professor and Huffington Foundation Distinguished Chair in the Department of Neurology at McGovern Medical School at UTHealth Houston. The research team’s conclusions were just released in Lancet Neurology.
About the Author
